CC-401

CAT: 804-HY-13022A-01Size: 1 mgDry Ice: NoHazardous: No
1 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CC-401 is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
CAS Number
[395104-30-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
JNK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cc-401.html
Purity
99.63
Solubility
DMSO : 40 mg/mL (ultrasonic)
Smiles
C1(C2=CC=CC(OCCN3CCCCC3)=C2)=NNC4=C1C=C(C=C4)C5=NC=NN5
Molecular Formula
C22H24N6O
Molecular Weight
388.47
Precautions
H302, H315, H319, H335
References & Citations
[1]Ma FY, et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol. 2007 Feb;18 (2) :472-84.|[2]Vasilevskaya IA, et al. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res. 2015 Sep 15;21 (18) :4143-52.|[3]Ma FY, et al. Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Invest. 2009 Apr;89 (4) :470-84.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
JNK
Citation 01
Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|Mol Cancer Res. 2016 Aug;14 (8) :753-63.|Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2024 Dec 9:145:113781.|Science. 2017 Dec 1;358 (6367) :eaan4368.